Allogenica develops allogenic CAR-T cells using donor stem cells for cancer treatment.
Allogenica has raised $2.7M in total funding. The most recent round was Grant. The last funding was announced in March 2025.
Allogenica's investors include France 2030.
Allogenica is headquartered in Lyon, France.
Allogenica develops allogenic CAR-T cells using donor stem cells for cancer treatment.
Allogenica is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Allogenica — Funding & Investors." VCBacked, March 19, 2025, https://www.vcbacked.co/company/allogenica. Accessed September 30, 2026.
VCBacked. (2025). Allogenica — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/allogenica
{{cite web |title=Allogenica — Funding & Investors |url=https://www.vcbacked.co/company/allogenica |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated